Suffers’ Lose Sleep After Philips’ Recall Of Sleep Apnea Machine: WSJ
Millions of Koninklijke Philips NV’s (NYSE:PHG) CPAP machines and ventilators are under a recall posing severe health problems, as many people are…
ResMed Q4 EPS $1.35 Beats $1.28 Estimate, Sales $876.10M Beat $783.18M Estimate
ResMed (NYSE:RMD) reported quarterly earnings of $1.35 per share which beat the analyst consensus estimate of $1.28 by 5.47 percent. This is a 1.5 percent increase over earnings of $1.33 per share from the same period
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 4)
Earnings Scheduled For August 5, 2021
Companies Reporting Before The Bell
• OneSpaWorld Holdings (NASDAQ:OSW) is projected to report quarterly loss at $0.20 per share on revenue of $6.42 million.
Stocks That Hit 52-Week Highs On Wednesday
Before 10 a.m. ET Wednesday, 138 stocks hit new 52-week highs.
The Daily Biotech Pulse: Pfizer’s Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 3)
Expert Ratings for ResMed
Within the last quarter, ResMed (NYSE:RMD) has observed the following analyst ratings:
Last 30 Days
1 Month Ago
2 Months Ago
Needham Downgrades ResMed to Hold
Needham analyst Mike Matson downgrades ResMed (NYSE:RMD) from Buy to Hold.